Home > Insider Trading > Filing (0001209191-15-002172)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
816284	Celgene Corp	CELG	Pharmaceutical Preparations (2834)	222711928

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1247024	Gilla Kaplan	C/O Celgene Corporation 86 Morris Avenue Summit NJ 07901		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2015-01-02	45,536	$16.21	45,536	No	4	M	Indirect	By family trust
Common Stock	Disposition	2015-01-02	45,536	$113.47	0	No	4	S	Indirect	By family trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	By family trust
No	4	S	Indirect	By family trust

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2015-01-02	45,536	$0.00	45,536	$16.21

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2015-12-29	No	4	M	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	79,508	Direct

Footnotes

The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The price reported in Column 4 is a weighted average price. These shares were sold by two family trusts (the trustee of which is Dr. Kaplan's brother-in-law and the beneficiaries of which are Dr. Kaplan's immediate family members) pursuant to Rule 10b5-1 plans in multiple transactions at prices ranging from $112.65 to $114.35, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.
The option was fully exercisable.
The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan.